Dingwei Ye
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Research top 1%
- Cancer, Lipids, and Metabolism
- MicroRNA in disease regulation
Papers in
-
- Prostate Cancer Treatment and Research 59
- Renal cell carcinoma treatment 29
- Prostate Cancer Diagnosis and Treatment 20
- Oncology 41
- Cancer Treatment and Pharmacology 11
- Cancer Immunotherapy and Biomarkers 11
- Co-authors
- Kim N. (20 shared papers)Mustafa Özgüroğlu (15 shared papers)Karim Fizazi (11 shared papers)Nobuaki Matsubara (8 shared papers)A. Rodrı́guez-Antolı́n (6 shared papers)Luis Fein (6 shared papers)Andrew Protheroe (6 shared papers)Susan Feyerabend (6 shared papers)
- Journals
- Journal of Clinical Oncology (46 papers)Asian Journal of Andrology (5 papers)The Prostate (4 papers)British Journal of Urology (4 papers)Frontiers in Oncology (3 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Dingwei Ye
129 papers receiving 5.2k citations
Dingwei Ye's Hit Papers
Peers
Comparison fields: 5 of 84
- Pulmonary and Respiratory Medicine 3.6k
- Cancer Research 1.1k
- Oncology 724
- Radiology, Nuclear Medicine and Imaging 583
- Endocrinology, Diabetes and Metabolism 348
Countries citing papers authored by Dingwei Ye
This map shows the geographic impact of Dingwei Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dingwei Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dingwei Ye more than expected).
Fields of papers citing papers by Dingwei Ye
This network shows the impact of papers produced by Dingwei Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dingwei Ye. The network helps show where Dingwei Ye may publish in the future.
Co-authors
The 25 scholars most cited alongside Dingwei Ye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 140 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2017 | 1478 |
| 2 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2019 | 943 |
| 3 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2019 | 549 |
| 4 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Hit paper breakdown → | 2021 | 309 |
| 5 | 2010 | 278 | |
| 6 | 2016 | 272 | |
| 7 | Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial Hit paper breakdown → | 2023 | 112 |
| 8 | 2023 | 75 | |
| 9 | 2019 | 75 | |
| 10 | 2013 | 58 | |
| 11 | 2021 | 49 | |
| 12 | 2009 | 44 | |
| 13 | 2022 | 40 | |
| 14 | 2017 | 40 | |
| 15 | 2017 | 38 | |
| 16 | [Epidemiology of prostate cancer in China: an overview and clinical implication]. | 2015 | 34 |
| 17 | 2014 | 32 | |
| 18 | 2023 | 31 | |
| 19 | 2015 | 31 | |
| 20 | 2021 | 30 |
About Dingwei Ye
Dingwei Ye is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Surgery and Cancer Research, having authored 140 papers that have together received 5.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (59 papers), Renal cell carcinoma treatment (29 papers), Radiopharmaceutical Chemistry and Applications (21 papers), Prostate Cancer Diagnosis and Treatment (20 papers), Bladder and Urothelial Cancer Treatments (16 papers), Cancer Treatment and Pharmacology (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.6k citations), Cancer Research (1.1k citations), Oncology (724 citations), Radiology, Nuclear Medicine and Imaging (583 citations) and Endocrinology, Diabetes and Metabolism (348 citations). Dingwei Ye has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Kim N., Mustafa Özgüroğlu, Karim Fizazi, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Luis Fein, Andrew Protheroe, Susan Feyerabend, B. Yа. Alekseev and Peter De Porre. Their work appears in journals such as Journal of Clinical Oncology, Asian Journal of Andrology, The Prostate, British Journal of Urology and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.